Modern challenges in infection prevention: encapsulated organisms in the era of novel complement inhibitors.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 41455584.
- Also identified by DOI 10.1016/j.kint.2025.12.014.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Complement inhibitors are now approved for use in atypical hemolytic uremic syndrome, IgA nephropathy, and C3 glomerulopathy. They are being studied widely in kidney disease, and more indications may soon arise. This review addresses an approach to preventing infectious complications, particularly encapsulated organism infections, and will hopefully serve as guidance for nephrologists utilizing these agents.
Medical subject headings
- Complement Inactivating Agents
- Infection Control